

Macular Edema - Pipeline Review, H1 2020

<https://marketpublishers.com/r/M3A3D94E0B7EN.html>

Date: June 2020

Pages: 92

Price: US\$ 2,000.00 (Single User License)

ID: M3A3D94E0B7EN

Abstracts

Macular Edema - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Macular Edema - Pipeline Review, H1 2020, provides an overview of the Macular Edema (Ophthalmology) pipeline landscape.

Macular edema is swelling or fluid retention in a specialized part of the retina called the macula. Symptoms of macular edema include blurred or wavy central vision and/or colors appear changed. There are many causes of macular edema. It is frequently associated with diabetes, where damaged blood vessels in the retina begin to leak fluids, including small amounts of blood, into the retina. Other causes include retinal vein occlusion, side effects of certain medications and certain genetic disorders, such as retinoschisis or retinitis pigmentosa.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Macular Edema - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Macular Edema (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Macular Edema (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-

Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 1, 1, 1, 2, 11, 1 and 1 respectively.

Macular Edema (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Macular Edema (Ophthalmology).

The pipeline guide reviews pipeline therapeutics for Macular Edema (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Macular Edema (Ophthalmology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Macular Edema (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Macular Edema (Ophthalmology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Macular Edema (Ophthalmology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Macular Edema (Ophthalmology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Macular Edema - Overview
- Macular Edema - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Macular Edema - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Macular Edema - Companies Involved in Therapeutics Development
- Anew Oncology Inc
- AsclepiX Therapeutics Inc
- Celon Pharma SA
- Clearside BioMedical Inc
- Coherus BioSciences Inc
- F. Hoffmann-La Roche Ltd
- Formycon AG
- Lupin Ltd
- Luye Pharma Group Ltd
- Mabion SA
- OMEICOS Therapeutics GmbH
- PharmAbcine Inc
- Polus Inc
- Profarma
- Sustained Nano Systems LLC
- Taiwan Liposome Co Ltd
- Targeted Therapy Technologies LLC
- Tarsius Pharma Ltd
- Xbrane Biopharma AB
- Macular Edema - Drug Profiles
- ACX-107 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress

afibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

afibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

afibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

afibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

afibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bevacizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Macular Edema - Dormant Projects

Macular Edema - Discontinued Products

Macular Edema - Product Development Milestones

Featured News & Press Releases

Apr 28, 2020: Clearside Biomedical revises NDA resubmission timeline and XIPERE commercial partnership with Bausch Health

Jan 28, 2020: Bausch Health and Clearside Biomedical announce publication of PIVOTAL phase 3 data ON XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) in Ophthalmology

Aug 22, 2019: Clearside Biomedical provides new drug application update for XIPERE (triamcinolone acetonide suprachoroidal injectable suspension)

Jul 31, 2019: Clearside Biomedical announces multiple oral presentations delivered at the American Society of Retinal Specialists (ASRS) Annual Meeting

May 01, 2019: Clearside Biomedical presents on Triamcinolone at the American Uveitis Society Spring Meeting 2019

Apr 18, 2019: Clearside Biomedical announces presentations on its Suprachoroidal Space injection platform with Triamcinolone Acetonide at upcoming medical meetings

Feb 20, 2019: Clearside Biomedical receives notification of FDA acceptance of NDA filing for XIPIRE (triamcinolone acetonide ophthalmic suspension) for suprachoroidal injection with PDUFA Date Set for October 19, 2019

Jan 20, 2019: Presentation of Clearside Biomedical's Extension Study of PEACHTREE for XIPIRE Exhibits Durability Following Second Dose

Dec 19, 2018: Clearside Biomedical submits New Drug Application for XIPIRE for the treatment of Macular Edema associated with Uveitis

Oct 29, 2018: Presentation of additional analyses of Clearside's PEACHTREE clinical trial data further supports potential of XIPIRE in treating uveitic macular edema

Oct 22, 2018: CLEARSIDE, XIPIRE and PEACHTREE to be front and center at AAO 2018

Sep 18, 2018: Positive PEACHTREE Data to be Highlighted at EURETINA 2018

Sep 13, 2018: Data from Clearside Biomedical's pivotal phase 3 PEACHTREE clinical trial in macular edema associated with non-infectious uveitis to be presented at the Retina Society 51st Annual Scientific Meeting

Sep 12, 2018: Single suprachoroidal steroid injection boosts visual acuity in patients with macular edema

Jul 16, 2018: Clearside Biomedical to Present Data from its Pivotal Phase 3 (PEACHTREE) Trial in Macular Edema Associated with Uveitis at the 2018 American Society of Retina Specialists Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Macular Edema, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Macular Edema - Pipeline by Anew Oncology Inc, H1 2020

Macular Edema - Pipeline by AsclepiX Therapeutics Inc, H1 2020

Macular Edema - Pipeline by Celon Pharma SA, H1 2020

Macular Edema - Pipeline by Clearside BioMedical Inc, H1 2020

Macular Edema - Pipeline by Coherus BioSciences Inc, H1 2020

Macular Edema - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020

Macular Edema - Pipeline by Formycon AG, H1 2020

Macular Edema - Pipeline by Lupin Ltd, H1 2020

Macular Edema - Pipeline by Luye Pharma Group Ltd, H1 2020

Macular Edema - Pipeline by Mabion SA, H1 2020

Macular Edema - Pipeline by OMEICOS Therapeutics GmbH, H1 2020

Macular Edema - Pipeline by PharmAbcine Inc, H1 2020

Macular Edema - Pipeline by Polus Inc, H1 2020

Macular Edema - Pipeline by Profarma, H1 2020

Macular Edema - Pipeline by Sustained Nano Systems LLC, H1 2020

Macular Edema - Pipeline by Taiwan Liposome Co Ltd, H1 2020

Macular Edema - Pipeline by Targeted Therapy Technologies LLC, H1 2020

Macular Edema - Pipeline by Tarsius Pharma Ltd, H1 2020

Macular Edema - Pipeline by Xbrane Biopharma AB, H1 2020

Macular Edema - Dormant Projects, H1 2020

Macular Edema - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Macular Edema, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Anew Oncology Inc
AsclepiX Therapeutics Inc
Celon Pharma SA
Clearside BioMedical Inc
Coherus BioSciences Inc
F. Hoffmann-La Roche Ltd
Formycon AG
Lupin Ltd
Luye Pharma Group Ltd
Mabion SA
OMEICOS Therapeutics GmbH
PharmAbcine Inc
Polus Inc
Profarma
Sustained Nano Systems LLC
Taiwan Liposome Co Ltd
Targeted Therapy Technologies LLC
Tarsius Pharma Ltd
Xbrane Biopharma AB

I would like to order

Product name: Macular Edema - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/M3A3D94E0B7EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M3A3D94E0B7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970